Inflammatory bowel disease (IBD) represents a group of diseases that cause chronic inflammation (pain and swelling) of the intestines. Crohn's disease and ulcerative colitis are examples of IBD and both of them have an impact on the digestive system.
Crohn's disease and ulcerative colitis have similar symptoms that are abdominal pain, diarrhea and fatigue. There is no single test that can diagnose either condition. A complete blood count (CBC) and a stool test are performed to look for signs of intestinal inflammation. In addition, tests such as colonoscopy and endoscopy can be used to diagnose IBD. Colonoscopy is a procedure used to examine the large and small intestines. Endoscopic ultrasound (EUS) is used to look for swelling and ulcers in the digestive tract.
A variety of medications may be used to treat IBD, including aminosalicylates, corticosteroids (such as prednisone), immunomodulators, and the newest class of IBD medications, known as "biologics." Pneumococcal vaccination is recommended for IBD patients to prevent infections.
Market Dynamics
Market players are focused on research and development activities for the treatment of ulcerative colitis, this could contribute to the growth of the global inflammatory bowel disease market over the forecast period. For instance, on June 29, 2021, AbbVie Inc., a research-based biopharmaceutical company, announced that RINVOQ (upadacitinib) (15 mg or 30 mg, once daily) met the primary endpoint of clinical remission and all secondary endpoints at one year (week 52) in the Phase III ulcerative colitis maintenance study.
Market players are focusing on product launches, which is expected to strengthen their position in the global inflammatory bowel disease market. For instance, on November 18, 2019, Pfizer Inc., a multinational pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved ABRILAD (adalimumab-afzb) as a biosimilar to Humira (adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, and ulcerative colitis.
Market players are involved in expanding their global presence by adopting strategies such as acquisitions and partnerships, this is expected to drive the growth of the global inflammatory bowel disease market. For instance, on May 17, 2021, Landos Biopharma Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for autoimmune disease patients, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients, announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China and selected Asian markets. Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD).
Key features of the study:
- This report provides an in-depth analysis of global inflammatory bowel disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global inflammatory bowel disease market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Johnson & Johnson Services Inc., AbbVie Inc., Takeda Pharmaceutical Company Ltd., UCB Pharma S.A., Pfizer Inc., Bristol Myers Squibb Co., Roche Holding AG, GlaxoSmithKline Plc, Eli Lilly & Company, and Novartis International AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global inflammatory bowel disease market
Detailed Segmentation:
- Global Inflammatory Bowel Disease Market, By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- Global Inflammatory Bowel Disease Market, By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- Global Inflammatory Bowel Disease Market, By Route of Administration:
- Global Inflammatory Bowel Disease Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inflammatory Bowel Disease Market, By Region:
- North America
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Corticosteroids
- Aminosalicylates
- TNF Inhibitors
- Immunosuppressant
- Antibiotics
- Others
- By Disease Indication:
- Ulcerative Colitis
- Crohn’s Disease
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Johnson & Johnson Services Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AbbVie Inc.
- Takeda Pharmaceutical Company Ltd.
- UCB Pharma S.A.
- Pfizer Inc.
- Bristol Myers Squibb Co.
- Roche Holding AG
- GlaxoSmithKline Plc
- Eli Lilly & Company
- Novartis International AG
“*” marked represents similar segmentation in other categories in the respective section.
